90-Minute RITUXAN Infusion for Appropriate Previously Untreated DLBCL and Follicular NHL Patients in Cycles 2-8
If patients did not experience a Grade 3 or 4 infusion related adverse event during Cycle 1, a 90-minute infusion can be administered in Cycle 2 with a glucocorticoid-containing chemotherapy regimen.
The 90-minute RITUXAN Infusion can be Administered to Patients who1,2,7:
- Have previously untreated DLBCL or follicular lymphoma, receiving R-CHOP or R-CVP, respectively
- Are ≥18 years of age
- Have an ECOG PS 0-2
- Have a circulating lymphocyte count ≤5,000/µL at the start of Cycle 2
- Did not experience any infusion-related serious adverse event (SAE) or Grade 3/4 infusion-related reaction (IRR) in Cycle 1
- Do not have significant cardiovascular disease*
- Patients in Stage 3 or 4 of DLBCL and follicular lymphoma were included in the RATE trial7
- All patients were premedicated with acetaminophen and an antihistamine prior to RITUXAN administration1
- Patients had a glucocorticoid component of R-CHOP or R-CVP administered prior to RITUXAN. No other glucocorticoids were allowed1,7
*Per the RATE trial, clinically significant cardiovascular disease is defined as uncontrolled hypertension, myocardial infarction, or unstable angina; New York Heart Association (NYHA) Classification Grade II or greater congestive heart failure; a ventricular arrhythmia requiring medication within 1 year prior to Day 1; or NYHA Grade II or greater peripheral vascular disease on Day 1.2
The 90-minute RITUXAN Infusion Rate for Appropriate Patients is1:
- 20% of the total dose over the first 30 minutes (75 mg/m2)
- 80% of the total dose over the following 60 minutes (300 mg/m2)
- If the 90-minute infusion is tolerated in Cycle 2, the same rate can be used when administering the remainder of the treatment regimen (through Cycle 6 or 8)